• Users Online: 221
  • Print this page
  • Email this page
Year : 2017  |  Volume : 10  |  Issue : 2  |  Page : 97-106

Diagnosis and systemic therapy for hepatobiliary cancer

Medical Department 1, University Hospital Erlangen, Erlangen, Germany

Correspondence Address:
Steffen Zopf
Medical Department 1, University Hospital Erlangen, Erlangen
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.7707/hmj.743

Rights and Permissions

Cancer of the liver, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC), is the second most common cause of cancer-related death, and its incidence rate is increasing. Clinical diagnosis is made by imaging methods based on contrast-enhanced techniques; some special types that include mixed differentiation may be picked up on biopsy. Advanced tumour stages are treated with systemic therapy. In HCC, therapy with the multikinase inhibitor sorafenib is established and new second-line therapies are expected. In CC, however, gemcitabine and cisplatin is standard in first-line therapy. This review highlights the diagnostic possibilities and current developments in the systemic therapy of HCC and CC.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded54    
    Comments [Add]    

Recommend this journal